Refine by
Mrsa Articles & Analysis
69 news found
Methicillin-resistant Staphylococcus aureus (MRSA) is described by the National Institute for Occupational Safety and Health (NIOSH) as a potentially dangerous type of staph bacteria. ...
The agency warns that anyone can get a MRSA infection or carry MRSA. The risks increase for people with hospitalizations or nursing home stays, skin-to-skin contact with others, and exposure to crowded and unhygienic places. ...
Their newest production discusses World MRSA Awareness Month which takes place each October. “Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staph that can be resistant to several antibiotics,” said Paul Cochrane, President of Cochrane & Associates and the IAQ Video Network. “Since 2009, the MRSA ...
The study was performed using two representative species of bacteria – Gram-positive methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative Pseudomonas aeruginosa. The irrigation solutions evaluated in the study involved an array of antimicrobial technologies and preservatives, including acids, surfactants, chlorhexidine gluconate (CHG), benzalkonium chloride ...
Various types include: · Methicillin-resistant Staphylococcus aureus (MRSA) · Methicillin-susceptible Staphylococcus aureus (MSSA) · Vancomycin-intermediate Staphylococcus aureus (VISA) · Vancomycin-resistant Staphylococcus aureus (VRSA) “These infections may include bacteremia or sepsis, pneumonia, endocarditis ...
XF-73 Nasal targeting peak sales potential of $1 billion in its major target markets Phase 3 patient recruitment could start in 2024 subject to completing an XF-73 Nasal partnering deal in 2023 XF-73 Nasal is the lead drug candidate developed from Destiny Pharma’s XF platform and it is initially being developed for the prevention of post-surgical staphylococcal infections, such as ...
XF-73 XF-73 Nasal is a novel drug being developed by Destiny Pharma to eradicate S. aureus (SA), including MRSA from the nose before surgery to prevent post-surgical infection. ...
Pravibismane exhibits broad-spectrum, potent in vitro activity against chronic respiratory infection and chronic wound relevant pathogens and their biofilms including NTM, multidrug resistant P. aeruginosa and MRSA. Pravibismane has also demonstrated safety in multiple clinical studies including treatment of patients with diabetic foot infections and patients with serious ...
Pravibismane exhibits broad-spectrum, potent in vitro activity against pathogens and their biofilms including MRSA, CRE, and multidrug resistant P. aeruginosa. About Microbion Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. ...
This parallels the top-line results from a US Phase 2 study announced earlier this week which showed that a single, 5-minute treatment of Ondine’s nasal photodisinfection significantly reduces Staphylococcus aureus (including MRSA) in pre-surgical patients. “Overuse of antibiotics over decades has caused adaptation in many microbes, and we now see multidrug ...
“Infections from drug-resistant organisms, whether it be C. auris, C. diff, MRSA, or another superbug, can be difficult to treat, costly, and deadly. ...
The nose and upper airway have been identified as the primary reservoir for many threatening pathogens including MRSA, Candida auris, and SARS-CoV-2. Ondine’s Steriwave nasal photodisinfection therapy can rapidly and painlessly eradicate pathogens in the nose and is currently being clinically trialled for the suppression of SARS-CoV-2 infection and transmission. ...
In in vitro studies, pravibismane exhibits broad-spectrum, potent activity against DFI-relevant pathogens and their biofilms including MRSA and drug resistant P. aeruginosa. In a randomized, double-blind, placebo-controlled Phase 1b trial treating patients with chronic moderate to severe diabetic foot ulcer infection, topical pravibismane treatment plus standard of care ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces completion of the Phase I clinical trial for ALS-4 (a first in-class anti-virulence based small molecule drug targeting infections caused by ...
The National Institute for Occupational Safety and Health (NIOSH) describes MRSA as a potentially dangerous type of staph bacteria. MRSA infections were traditionally associated with hospitalization or other health care-associated risk factors, but this is no longer the case. ...
Methicillin-resistant Staphylococcus aureus (MRSA) is described by the National Institute for Occupational Safety and Health (NIOSH) as a potentially dangerous type of staph bacteria. ...
Their newest production discusses methicillin-resistant Staphylococcus aureus (MRSA) and potential exposure risks in the work environment. “MRSA are bacteria that are resistant to an antibiotic known as methicillin, as well as other antibiotics in many cases,” said Paul Cochrane, President of Cochrane and Associates and the IAQ Video Network. ...
“At CSC we have always helped customers and strategic partners prepare for, prevent and respond to disease outbreaks from Legionellosis, to MRSA, to Clostridium difficile. COVID19 is just the newest item on a long list. ...
While much of the media’s attention has been focused on the novel coronavirus that spread across the globe this year, SARS-CoV-2 is not the only emerging threat. Just before reports of the initial outbreak of COVID-19 last year, the Centers for Disease Control and Prevention (CDC) published an update to the agency’s first Antibiotic Resistance Threats in the United States (AR Threats ...
“The presence of drug-resistant pathogens, such as C. diff and MRSA, on surfaces within a facility can lead to serious and sometimes deadly infections. ...